10-QHealthcare

NOVAVAX, INC.

NVAX · Period ending 2026-09-30 · Filed 2026-11-05 · Updated

In short

NOVAVAX, INC. (NVAX) has revenue up 64.7% to $1.1B year on year. Its net margin is 39.2%. Fisclear flags 2 high-severity risks, led by: Negative operating cash flow of $244.6M — the core business consumed more cash than it generated. How we calculate this

Valuation

Healthcare
Live · Yahoo Finance

Price

$7.47

P/S (TTM)

3.0x

Price ÷ revenue per share

Beta

2.72

High volatility vs market

PEG Ratio

1.3x

P/E ÷ earnings growth rate

52-Week Range

$6.36$7.47 now$13.39

Decision Context

Altman Z-Score indicates financial distress risk. Review debt levels and cash runway before any position sizing decision.

Based on filing period ending Sept 2026

FisclearScore is a quantitative model using public financial data and sector median benchmarks (refreshed monthly). Not financial advice. Always conduct independent due diligence.

NVAX vs

Macro Context

Fed Funds Rate

3.88%

Accommodative

10-Year Treasury

5.13%

2026-10-01

Unemployment

4.1%

Near full employment

CPI Index

336.3

2026-09-01

M2 Money Supply

$23.4T

2026-09-01

The Federal Funds rate stands at 3.88% — a moderately elevated rate environment that raises borrowing costs across the economy; 10-year Treasury yields are at 5.13%, setting the benchmark for long-term corporate borrowing; Unemployment stands at 4.1%; Industrial production index is at 104.0; M2 money supply is $23.4T; CPI index stands at 336.3.

SWOT Analysis — NVAX

Inflationary Boom
Macro lens (Inflationary Boom): Rising costs and tighter margins amplify financial risks in this regime.
✦

Strengths

  • Net Income: $440.3M (+334.8% YoY) — Profit grew 335% — the company kept more of each dollar earned.

  • EPS (Diluted): $2.58 (+309.8% YoY) — Earnings per share rose 310% — each share earned more.

  • Revenue: $1.1B (+64.7% YoY) — Revenue grew 65% — the company sold more goods or services than the prior year.

◈

Weaknesses

  • Operating Cash Flow: -$244.6M (-180.3% YoY) — Negative operating cash flow — the business consumed more cash than it produced from operations.

  • Total Assets: $1.2B (-24.6% YoY) — Total assets shrank 25% — the balance sheet contracted.

  • R&D spending is 30% of revenue — heavy investment in future growth, but also a drag on current profitability.

  • Beta of 2.72x — this stock moves significantly more than the broader market, amplifying both gains and drawdowns.

◎

Opportunities

No clear opportunities identified at this time.

⚠

Threats

  • Negative operating cash flow of $244.6M — the core business consumed more cash than it generated.

  • Total liabilities are 111% of total assets — the balance sheet is heavily leveraged with limited equity cushion.

Year-over-Year Changes

Net Income

$440.3M

was -$187.5M

+334.8%

Profit grew 335% — the company kept more of each dollar earned.

EPS (Diluted)

$2.58

was $-1.23

+309.8%

Earnings per share rose 310% — each share earned more.

Operating Cash Flow

-$244.6M

was -$87.3M

−180.3%

Negative operating cash flow — the business consumed more cash than it produced from operations.

Revenue

$1.1B

was $682.2M

+64.7%

Revenue grew 65% — the company sold more goods or services than the prior year.

Total Assets

$1.2B

was $1.6B

−24.6%

Total assets shrank 25% — the balance sheet contracted.

Risk Flags

2 high · 0 medium · 2 low
  • ⚠ High

    Negative operating cash flow of $244.6M — the core business consumed more cash than it generated.

  • ⚠ High

    Total liabilities are 111% of total assets — the balance sheet is heavily leveraged with limited equity cushion.

  • ○ Low

    R&D spending is 30% of revenue — heavy investment in future growth, but also a drag on current profitability.

  • ○ Low

    Beta of 2.72x — this stock moves significantly more than the broader market, amplifying both gains and drawdowns.

Technical Signals

Daily closes · 1-year data

NOVAVAX, INC.: common questions

Is NOVAVAX, INC. profitable?

Yes. NOVAVAX, INC. made a net profit of $440M in its latest fiscal year (fiscal 2025), a net margin of 39.2%.

Is NOVAVAX, INC.'s revenue growing?

Yes. Revenue grew 64.7% year on year, to $1.1B.

Does NOVAVAX, INC. pay a dividend?

No dividend is currently expected from NOVAVAX, INC., according to the latest market data.

What are the main risks for NOVAVAX, INC.?

Fisclear's checks flag 2 medium- or high-severity risks. The most serious: Negative operating cash flow of $244.6M — the core business consumed more cash than it generated.

Answers are generated from the figures in this report (updated 8 Nov 2026). Information, not investment advice.

Latest News

via Finnhub

Filing History — NVAX

Get the weekly digest

5 company reports + macro context every week, free. No spam.

  • Unlimited goal simulations
  • 5 free company report summaries per day
  • Weekly financial insights newsletter

External Links

Trade NVAX

Links open broker research pages. Not an endorsement or recommendation.

Research NOVAVAX, INC.

Data sourced from SEC EDGAR, FRED (Federal Reserve Economic Data), and Yahoo Finance. For informational purposes only. Not financial advice.